| 货号 | DY196018 |
|---|---|
| 品牌 | abinScience |
| 样本类型 | Plasma, Serum |
| 灵敏度 | 0.156 μg/ml |
| 检测范围 | 0.31-5 μg/mL |
| Accession号 | P08581 |
| 应用 | ELISA |
| 检测方法 | Colorimetric |
| 实验类型 | Quantitative |
| 回收率 | 80-120% |
| 运输 | 2-8 ℃ |
| 稳定性和存储 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| 规格 | Emibetuzumab |
| 别名 | LA480, LY-2875358, CAS: 1365287-97-3 |
| 背景 | Emibetuzumab (as known as LY2875358) is a humanized immunoglobulin G4 monoclonal bivalent anti-MET antibody that blocks MET signaling. This drug was developed by Eli Lilly & Company and has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others. In preclinical models, emibetuzumab inhibited growth of tumors that are dependent on MET, including tumors that exhibit HGF-dependent and HGF-independent biology. Administration of a single dose of emibetuzumab resulted in continuous reduction of MET protein expression for 14 days in mouse xenografts. Emibetuzumab demonstrated dose-dependent, single-agent activity in various MET-expressing tumor models, and additive effects were observed in combination with erlotinib for reducing tumor volume in lung cancer mouse xenograft models. In Phase 1 dose escalation studies, emibetuzumab monotherapy was well tolerated in patients with advanced solid tumors, including gastric cancer, with no dose-limiting toxicities. |
| Note | For Research Use Only. |
027-87433958/17302791434
武汉东湖新技术开发区神墩四路666号研发楼B区3层东
